The EarlySense Central Display System is intended to provide remote central monitoring and display of information as recorded by multiple EarlySense bedside units, on a central remote screen. The system can be used in hospital type and clinic environment.

Device Description

The EarlySense Central Display System (CDS) is a system which includes EarlySense developed application software, installed on standard off-the-shelf PC computer with a computer screen. The system also uses standard off-the shelf communication and IT hardware.

The CDS is intended to communicate with multiple EarlySense Bedside monitoring devices (cleared as K131379 and K120465), in order to display the information as it is monitored on the bedside units on a central remote screen. The users can access the user interface of the individual bedside units via the CDS's screen and view or adjust bedside units' parameters, e.g. change settable parameters, such as alert thresholds.

The communication is performed through TCP/IP protocol, either via standard wired or via wireless LAN communication. The transmitted information from Bedside Unit to CDS and backwards includes alert information and physiological parameters (such as patient in / out of bed status, heart rate, respiration rate, motion rate and Sp02, if monitored at bedside unit, as well as room and bed number, etc.). The CDS can also format the alert information as obtained from Bedside units into a message that can be transmitted to external devices that can communicate with the CDS via standard TCP/IP port. In addition, a possibility to remotely view the CDS screen from a tablet or additional PC computer exists.

The accessories that can be possibly used with CDS system include:

. Computer Screen
. Keyboard and mouse
Additional hallway LCD/LED screen .
. External communication devices, like: pagers, etc.
Tablet or additional PC computer (to remotely view the CDS computer . screen)

AI/ML Overview

The provided text describes the EarlySense Central Display System (CDS) and its substantial equivalence to predicate devices, but it does not contain the detailed information necessary to answer most of the questions about acceptance criteria and a specific study proving the device meets those criteria.

The document is a 510(k) summary, which focuses on demonstrating substantial equivalence to legally marketed predicate devices, rather than a detailed report of a performance study with specific acceptance criteria.

Here's what can be extracted and what is missing:

1. Table of acceptance criteria and the reported device performance:

This information is not provided in the document. The document states that the modified EarlySense CDS System was subject to "the whole range of verification and validation tests," including:

Risk analysis
Software Verification and Validation
Performance Bench Testing

However, it does not specify what the acceptance criteria for these tests were, nor does it present the actual performance results in relation to such criteria. The conclusion simply states that the non-clinical tests demonstrate the device is "as safe, as effective, and performs as well as or better than the predicate devices."

Regarding a specific study proving the device meets acceptance criteria:

The document mentions "Performance Bench Testing" but provides no details on its methodology, sample size, or specific outcomes.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

This information is not provided. The document mentions "Performance Bench Testing" but does not detail the sample size or data provenance.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This information is not provided. The mention of "Performance Bench Testing" does not include details on how ground truth was established or by whom. The device is a central display system for physiological parameters, not an AI diagnostic device that typically requires expert-established ground truth in the same way.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This information is not provided.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This information is not provided. The device is a central display system for monitoring, not an AI for interpretation or assisting human readers in a diagnostic task that would typically warrant a MRMC study.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

The document implies "Performance Bench Testing" was done for the software algorithm as part of the system. The device itself is essentially a standalone software application displaying data from other bedside units. However, specific details of this testing (e.g., how "standalone" was measured) are not provided. The comparison is made against predicate devices which are also central display systems, implying a functional comparison rather than a human-in-the-loop versus algorithm-only comparison.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

This information is not provided. For a central display system, the "ground truth" for performance testing would likely involve ensuring accurate transmission and display of physiological parameters from the bedside units. This would typically be verified against the direct output of the bedside units or simulated data, rather than expert consensus or pathology.

8. The sample size for the training set

This information is not provided. The device is described as a software application that displays data from other units and allows for parameter adjustment. It does not appear to be an AI/ML device that requires a "training set" in the conventional sense for learning patterns or making predictions. It's a display and control interface.

9. How the ground truth for the training set was established

This information is not provided and is likely not applicable, as the device is not described as an AI/ML system requiring a training set with established ground truth.

Summary of what is present:

Device Description: The EarlySense Central Display System (CDS) is a software application installed on standard off-the-shelf PC hardware. It communicates with multiple EarlySense Bedside monitoring devices to remotely display physiological information (heart rate, respiration rate, motion rate, SpO2, in/out of bed status, etc.) and allows remote adjustment of bedside unit parameters.
Purpose of Review: This is a 510(k) premarket notification for an updated software version (1.1.2.2) of the CDS, demonstrating substantial equivalence to predicate devices (EarlySense Central Display Station, K121885, and Connex Central Station, K132807).
Performance Data Mentioned: The system underwent Risk analysis, Software Verification and Validation, and Performance Bench Testing.
Conclusion: Non-clinical tests demonstrate the device is "as safe, as effective, and performs as well as or better than the predicate devices."

The document focuses on the regulatory pathway of substantial equivalence rather than a detailed scientific and clinical performance study report.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with three abstract shapes above them. The logo is black and white.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

August 31, 2015

Earlysense Ltd. Dalia Argaman VP Clinical and Regulatory Affairs 12 Tzvi St Ramat Gan, 5250429, Israel

Re: K151006

Trade/Device Name: Earlysense Central Display System (CDS) Regulation Number: 21 CFR 870.2300 Regulation Name: Cardiac Monitor (Including Cardiotachometer and Rate Alarm) Regulatory Class: Class II Product Code: MSX, MWI Dated: June 1, 2015 Received: June 4, 2015

Dear Dalia Argaman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

{1}------------------------------------------------

the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Mitchell Stein

forBram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K151006

Device Name EarlySense Central Display Station (CDS)

Indications for Use (Describe)

Type of Use (Select one or both, as applicable):

☑ Prescription Use (Part 21 CFR 801 Subpart D)	☐ Over-The-Counter Use (21 CFR 801 Subpart C)
----------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(K) SUMMARY

EarlySense Central Display System (CDS)

I. SUBMITTER

EarlySense Ltd. 12 Tzvi St. Ramat Gan 5250429, Israel Phone: +972-3-7522330(ext.106); Fax: +972-3-7522340 Contact Person: Dalia Argaman E-mail: Dalia.Argaman@EarlySense.com Date Prepared: August 12, 2015

II. DEVICE

Device Common/Trade Name: EarlySense Central Display System (CDS) Classification Name: System Network and communication, physiological monitor (21 CFR Sec. 870.2300) Regulatory Class: II Product Code: MSX, MWI

III. PREDICATE DEVICES

Primary Predicate: EarlySense Central Display Station, K121885 Secondary Predicate: Connex Central Station, K132807 These predicates have not been subjects to a design-related recall.

IV. DEVICE DESCRIPTION

A traditional 510(k) is submitted to clear the updated Central Display Station System with the new software version 1.1.2.2

{4}------------------------------------------------

The accessories that can be possibly used with CDS system include:

. Computer Screen
. Keyboard and mouse
Additional hallway LCD/LED screen .
. External communication devices, like: pagers, etc.
Tablet or additional PC computer (to remotely view the CDS computer . screen)

{5}------------------------------------------------

V. INTENDED USE/INDICATIONS FOR USE

The Indications for Use statement of the EarlySense Central Display Station (CDS) is similar to its predicate devices: the modified Earlysense CDS is intended for remote view of the EarlySense bedside units monitoring data and it also allows to adjust the bedside units settable parameters by allowing remote view of the user interface of individual bedside units and adjusting the settable parameters from afar. These features were not present in the previous cleared version of the CDS, but are present in the secondary predicate, Connex Central Station, K132807, that is intended for central monitoring of patient data and alarms.

COMPARISON OF TECHNOLOGICAL CHARACTERISTICS VI. WITH THE PREDICATE DEVICES

The modified EarlySense CDS Systems share the similar fundamental functionality, the similar principle of operation, similar types of components, similar intended use and indications for use with the predicate devices.

The modified EarlySense Central Display Systems share the same technological principle with its predicate devices and at the high level, the subject and predicate devices are based on the same technological features:

. Similar to its predicates, the modified CDS is a software application that is developed by EarlySense and is installed on Off-the-shelf hardware (computer).
. Modified CDS system and its predicates are used for remote central monitoring and display of information as recorded by Bedside units.
. System hardware components are similar for all three systems and include: Standard PC with monitor, mouse, screen,

{6}------------------------------------------------

. Only the software is developed and produced by the manufacturers in modified CDS and its predicates, all the other parts of the system are bought off-the-shelf
. Modified CDS and its cleared CDS predicate remotely display and monitor exactly the same physiological parameters, such as: Heart Rate, Respiration Rate, Sp02, motion and bed exit features
Communication with the Bedside units is performed in exactly the . same way as in cleared device, through LAN and wireless LAN
Modified and cleared CDS systems do not perform analysis of data, but . only duplicate the data received from Bedside units
EarlySense and its predicate devices are used in the same clinical . environments- hospitals or hospital type and clinic environment

The following technological differences exist between the modified EarlySense CDS and its predicate devices:

. Modified CDS is able to remotely access separate Bedside units and adjust bedside unit's settable parameters from remote station. The new feature, didn't exist in cleared EarlySense CDS, but capability of adjusting bedside units parameters exists in Connex System

VII. PERFORMANCE DATA

The modified EarlySense CDS System was subject to the whole range of verification and validation tests:

1. Risk analysis (See Section 16 of the current submission)
1. Software Verification and Validation (See Section 16 of the current submission)
1. Performance Bench Testing (See Section 18 of the current submission)

The conclusions drawn from the non-clinical tests demonstrate that the device is as safe, as effective, and performs as well as or better than the predicate devices: EarlySense Central Display Station (K121885) and Connex Central Station, (K132807).

Regulation Number and Section

§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).

(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).